Lenin Palacios

#médico, #Oncólogo Clínico.

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🧬 #VHIO professionals from the Hereditary Cancer Genetics Group, led by @judithbalmana, participated in #ESHG2026.

@Estela131516 presented the #CANGUR project as an oral communication, while Adrià López-Fernández, Laura Durán-Lozano, Laia Peralta-Parada and Setareh Kompanian presented scientific posters on cancer genetics and precision medicine.

➡️ https://t.co/iocgF3LahJ

[Paolo Tarantino @PTarantinoMD]

The most important breast abstract from #ASCO26 is out. 4429 pts with ER+/HER2- BC randomized to SoC vs PAM50-directed adjuvant treatment. 19% had N2 dz (4-9 nodes), premenopausal pts received LHRHa. No benefit from chemo if ROR≤60. Looking forward to the full presentation.

[Yakup Ergün @dr_yakupergun]

Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study

Full text👇

https://t.co/f0jVnmCOYv

[Elvina Almuradova @Dr_ElvinaA]

A major 2026 meta-analysis by involving 15,000+ premenopausal women confirmed that ovarian function suppression (OFS) significantly reduces recurrence and breast cancer mortality in ER+ early breast cancer.
• Recurrence ↓ 21%
• Distant recurrence ↓ 2%
• Breast cancer mortality ↓ 26% in younger women
#BreastCancer #ERpositive #Oncology #OFS #Tamoxifen #ESMO #BreastOncology @Larvol @OncoAlert

[Paolo Tarantino @PTarantinoMD]

The approval of T-DXd for the (neo)adjuvant treatment of HER2+ breast cancer will add an invaluable tool to our arsenal. Yet, in this era of right-sizing, not all patients require T-DXd treatment to be cured. Some thoughts in my recent JCO editorial. https://t.co/tKCgzzbdiq

[Mustafa Özdoğan, MD @ozdogan_md]

Breaking the 40-year silence in Pancreatic Cancer!

The #FDA just granted Expanded Access for Daraxonrasib, a first-in-class multi-selective RAS(ON) inhibitor.

#PancreaticCancer #Oncology #PrecisionMedicine #MedTwitter #Daraxonrasib

[Dr Sarah Sammons @drsarahsam]

Ovarian function suppression is arguably the most important advancement for ER+ young women with breast cancer, markedly reducing recurrence.

Now more trials on how to support side effects for these women thrown into early menopause. #bcsm

[MV Chandrakanth @ChandrakanthMv]

HER2+ early breast cancer — can we omit chemotherapy?
PHERGain (5-year results):
• PET-guided strategy
• ~1/3 patients avoided chemotherapy
• Excellent outcomes in responders
Key takeaway:
👉 Response-adapted de-escalation is feasible in selected patients
⚠️ Phase II data
#BreastCancer #HER2 #Oncology #ESMOBreast2026 #MVOnco

[Dr Rishabh Jain @DrRishabhOnco]

Breast cancer is entering a chemo-free, ADC-driven, ctDNA-guided era.
ESMO Breast 2026 could quietly redefine practice.

Here are 10 trials you should NOT miss 👇

1️⃣ PHERGain-2
🧬 Early HER2+
👉 Chemo-free dual HER2 blockade strategy
🎯 Can we safely omit chemo?

2️⃣ TRAIN-4
🧬 Early HER2+
👉 Anthracycline-free ± escalation
🎯 Is less more?

3️⃣ DESTINY-Breast11
🧬 Neoadjuvant HER2+
👉 Trastuzumab deruxtecan vs standard
🎯 ADC replacing chemo?

4️⃣ HER2CLIMB-02
🧬 HER2+ metastatic
👉 Tucatinib + Trastuzumab emtansine
🎯 Brain mets control

5️⃣ SATEEN
🧬 Post-Trastuzumab deruxtecan setting
👉 Sequencing strategies
🎯 What after T-DXd?

6️⃣ TROPION-Breast04
🧬 HR+/HER2- metastatic
👉 Datopotamab deruxtecan
🎯 Next ADC wave

7️⃣ DESTINY-Breast06 (updates)
🧬 HER2-low / ultra-low
👉 Expanding Trastuzumab deruxtecan
🎯 Redefining HER2 biology

8️⃣ PERSEVERE
🧬 ctDNA-guided early BC
👉 MRD-based escalation/de-escalation
🎯 Precision adjuvant therapy

9️⃣ lidERA (Giredestrant)
🧬 Early ER+
👉 Giredestrant vs standard ET
🎯 SERDs moving early

🔟 CAMBRIA-2
🧬 ER+ high-risk
👉 Camizestrant
🎯 Endocrine backbone changing?

#OncoTwitter #MedTwitter #BreastCancer #ADC
@myESMO @ESMO_Open @stolaney1 @OncoAlert @OncBrothers @Larvol

[Paolo Tarantino @PTarantinoMD]

It’s that time of the year again! #ESMOBreast26 is only a few days away, and promises to bring new important data in breast oncology. This year’s key themes: tailoring therapy for HER2+ eBC, prospective data with ADC sequencing, use of MRD to guide treatment. See you in Berlin!

[Entisar saleh @Entisar_kilani]

Top 10 breast cancer updates by oncodaily breast .

https://t.co/1VyvBk6Y2Y
#breast #oncology #oncodaily

[Dr Preetam Jain @PreetamJainOnco]

Anthracycline Benefit in High-Risk Breast Cancer

1) Is it time to reconsider the role of Anthracyclines in HR+ HER2- Breast Cancer?

New data from the FLEX study reveals a striking 10.7% absolute iDFS benefit for a specific subset of patients. Here is why genomic subtyping matters more than ever.
🧵
#BreastCancer #Oncology #PrecisionMedicine

2) The study focused on patients identified by MammaPrint as High Risk 2 (MP2) and BluePrint as Luminal B .

For years, we’ve debated if TC is "enough." In this ultra-high-risk genomic group, the data suggests it might not be.
#OncTwitter #FLEXStudy

3) The Results (3-Year iDFS):

✅ ACT (Anthracycline-based): 100%
⚠️ TC (Non-Anthracycline): 89.3%

That’s a 10.7% absolute benefit at a median 3.2-year follow-up. In oncology, an absolute gain of this magnitude is a practice-changing signal.

4) Why does this matter?
Precision medicine isn't just about de-escalation; it’s about right-escalation.

5) By identifying MP2/Luminal B signatures, we can pinpoint patients who derive maximum benefit from more intensive regimens, ensuring we don't undertreat aggressive biology.

While we await longer-term follow-up, the FLEX data reinforces that genomic profiling is essential for tailoring adjuvant therapy.

2026 NCCN Guidelines Now Support This Approach

The NCCN now recognizes MammaPrint + BluePrint to identify which HR+/HER2- patients benefit most from anthracycline. Consequently, this marks the first endorsed genomic tool for this decision.

Individualized care = Better outcomes. 🎗️

Dr Preetam Jain
Medical Oncologist |
Director, OncoWorld Cancer Centre
#Mumbai #MedOnco

Here is the Link :

https://t.co/GMqubD4Nbv

@oncodaily
@OncoAlert @TheBreastOnline @ESMO_Open @oncologytube

[Paolo Tarantino @PTarantinoMD]

Based on D-PT02, T-DXd received an agnostic approval, although restricted to HER2 IHC 3+ tumors. This analysis looked at concordance between local and centralized HER2 score: 58%❗️A coin toss, determining access to T-DXd. We need more objective biomarkers. https://t.co/FgxrNeUoq2

[Allison Fitzgerald, MD, PhD @allisonoconn]

This is a very important study for clinical practice. In patients with breast cancer, adding alternative medicine to traditional cancer treatment REDUCED overall survival. The study reports patients who received alternative care were less likely to to complete standard care.

[Fondazione Gianni Bonadonna @FondazioneBona1]

In HER2+ breast cancer patients a neoadjuvant therapy with a selected taxane plus trastuzumab but without carboplatin leads to similar benefits in pathological complete response and improves tolerability
https://t.co/UCTAJ8JYDn
#FondazioneMichelangelo #CancerResearch #Oncology

[Brandon Luu, MD @BrandonLuuMD]

For breast cancer, alternative medicine alone was linked to a 267% higher mortality hazard.

Even when combined with standard treatment, mortality hazard was still 45% higher.

Modern oncology saves lives. Please consider using it.

[Aumilto Silva, MD. @aumilto]

TROPION-Breast02

Dato-DXd vs chemotherapy in 1L metastatic TNBC (IO-ineligible) → positive for PFS and OS

Efficacy (BICR):
• PFS: 10.8 vs 5.6 mo (HR 0.57, p<0.0001)
• OS: 23.7 vs 18.7 mo (HR 0.79, p=0.029)
• ORR: 63% vs 29%

• TROPION-Breast02 → IO-ineligible population
• ASCENT-03 → broader 1L TNBC population

Efficacy comparison (cross-trial, cautious):
• Dato-DXd → HR PFS 0.57 + OS benefit demonstrated
• Sacituzumab govitecan (ASCENT-03) → PFS benefit, OS not clearly positive (current data)

👉Important:
TROPION-Breast02 → includes early relapsing pts (DFI ≤12 mo)
• Dato-DXd: PFS + OS positive
• SG: PFS benefit; OS not clearly positive (current data)

→ Activity preserved in biologically aggressive early-relapse TNBC
→ Supports Dato-DXd as robust 1L option even in poor-prognosis pts

@Annals_Oncology @OncoAlert

👉 https://t.co/rmgtdYCVY6

[Elvina Almuradova @Dr_ElvinaA]

TROPION-Breast02 shows clear benefit of datopotamab deruxtecan (Dato-DXd) over chemotherapy in 1L advanced TNBC (IO-ineligible).

✔️ PFS and OS improved
✔️ Higher and more durable responses
✔️ Manageable safety profile

A promising new first-line option in a challenging setting.

#Oncology #TNBC #BreastCancer #larvol @OncoAlert @Larvol

[Paolo Tarantino @PTarantinoMD]

TROPION-Breast02 published in @Annals_Oncology: 1L therapy with Dato-DXd led to near doubling of PFS, ORR and significant OS benefit (vs chemo) in IO-ineligible mTNBC. New important option and new hope for one of the most aggressive forms of breast cancer. https://t.co/a7p4ivlYDW

[Yakup Ergün @dr_yakupergun]

Timeline of FDA and EMA tumour-agnostic indications

https://t.co/gXdS0pRwIs